Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
2006-05-17
2009-08-04
Spector, Lorraine (Department: 1646)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C530S388220, C530S388100, C530S388150, C530S387100, C530S391500, C530S391100
Reexamination Certificate
active
07569387
ABSTRACT:
Novel MK61 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing MK61 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with MK61 polypeptides.
REFERENCES:
patent: 5194596 (1993-03-01), Tischer et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5843789 (1998-12-01), Nomura et al.
patent: 6342351 (2002-01-01), Chen et al.
patent: 393438 (1990-10-01), None
patent: 422339 (1998-01-01), None
patent: WO 01/55206 (2001-08-01), None
patent: WO 01/55314 (2001-08-01), None
patent: WO 01/57182 (2001-08-01), None
Yount et al., Rat neutrophil defensins, J. immunol. 155:4476-4484, 1995.
GenBank Accession Q9H665, Transmembrane protein 149 precurson (U2 small nuclear RNA auxiliary factor 1-like 4), Mar. 1, 2001, accessed Jun. 10, 2008.
Wattanabe et al., Database GenEmbl, Accession No. AK026226, Sep. 29, 2000.
Lamerdin, Database GenEmbl, Accession No. AD000671, Dec. 10, 1997.
NCI/CGAP, Database EST, Accession No. AI372981, Feb. 16, 1999.
NCI/NINDS-CGAP, Database EST, Accession No. AI597639, May 12, 1999.
Vukicevic et al., 1996, PNAS USA 93:9021-9026.
Aderka, “The potential biological and clinical significance of the soluble tumor necrosis factor receptors,”Cytokine&Growth Factor Reviews7:231-240, 1996.
Banner et al., Crystal structure of the soluble human 55kd TNF receptor-human TNFβ complex: Implications for TNF receptor activation,Cell73:431-445, 1993.
Castro et al., “Fas modulation of apoptosis during negative selection of thymocytes,”Immunity5:617-627, 1996.
Chichepotiche et al., “Tweak, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis,”J. Biol. Chem. 272:32401-32410, 1997.
Fu et al., “Development and maturation of secondary lymphoid tissues,”Ann. Rev. Immunol. 17:399-433, 1999.
Grewal et al., “CD40 and CD154 in cell-mediated immunity,”Ann. Rev. Immunol. 16:111-135, 1998.
Guo et al., “Stimulatory effects of B7-related protein-1 on cellular and humoral immune responses in mice,”J. Immunol. 166:5578-5584, 2001.
Hahne et al., “April, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth,”J. Exp. Med., 188:1185-1190, 1998.
Han et al., “Molecular cloning of human p38 MAP kinase,”Biochimica et Biophysica Acta1265:224-227, 1995.
Idriss et al., “TNFα and the TNF receptor superfamily: Structure-function relationship(s),”Microsc. Res. Tech. 50:184-195, 2000.
Lacey et al., “Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation,”Cell93:165-176, 1998.
Lee et al., “A protein kinase involved in the regulation of inflammatory cytokine biosynthesis,”Nature372:739-746, 1994.
Locksley et al., “The TNF and TNF receptor superfamilies: integrating mammalian biology,”Cell104:487-501, 2001.
Madry et al., “The characterization of murine BCMA gene defines it as a new member of the tumor necrosis factor receptor superfamily,”International Immunology10:1693-1702, 1998.
Mauri et al., “LIGHT, a new member of the TNF superfamily, and lymphotoxin α are ligands for herpesvirus entry mediator,”Immunity8:21-30, 1998.
Mizushima et al., “pEF-BOS, a powerful mammalian expression vector,”Nucl. Acids Res.18:5322, 1990.
Nagata et al., “Fas and Fas ligand:lprandgldmutations,”Immunology Today16:39-43, 1995.
Naismith et al., “Modularity in the TNF-receptor family,”TIBS Trends Biochem. Sci.. 23:74-79, 1998.
Noelle, “CD40 and its ligand in host defense,”Immunity4:415-419, 1996.
Nophar et al., “Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type 1 TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor,”EMBO J. 9:3269-3278, 1990.
Shu et al., “TALL-1 is a novel member of the TNF family that is down-regulated by mitogens,”J. Leukocyte Biology65:680-683, 1999.
Smith et al., “A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins,”Science248:1019-1023, 1990.
Smith et al., “The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death,”Cell76:959-962, 1994.
Strasser et al., “FADD/MORTI, a signal transducer that can promote cell death or cell growth,”Intl. J. Biochem. Cell Biol. 31:533-537, 1997.
Tracey et al., “Tumor Necrosis Factor: A pleiotropic cytokine and therapeutic target,”Ann. Rev. Med. 45:491-503, 1994.
Wallach et al., “Soluble and cell surface receptors for tumor necrosis factor,”Agents Actions Suppl. 35:51-57, 1991.
Williams et al., “Cartilage destruction and bone erosion in arthritis: the role of tumour necrosis factor α,”Ann. Rheum. Dis. 59(suppll):i75-i80, 2000.
Yamada et al., “Initiation of liver growth by tumor necrosis factor: Deficient liver regeneration in mice lacking type I tumor necrosis factor receptor,”Proc. Natl. Acad. Sci.(U.S.A). 94:1441-1446, 1997.
International Search Report, PCT/US01/27631, European Patent Office.
Database EMBL Accession No. AI819838, XP002197573, Dec. 23, 1999, the whole document.
Database EMBL Accession No. AI597639, XP002197574, Mar. 4, 2000, the whole document.
Database EMBL Accession No. AI806948, XP002197575, Dec. 22, 1999, the whole document.
Database EMBL Accession No. BE254397, XP002197576, Jul. 14, 2000, the whole document.
Database EMBL Accession No. AI571409, XP002197577, Mar. 4, 2000, the whole document.
Database EMBL Accession No. AI090681, XP002197578, Mar. 3, 2000, the whole document.
Database EMBL Accession No. AW274489, XP002197579, Jan. 6, 2000, the whole document.
Database EMBL Accession No. AW553050, XP002197580, Mar. 13, 2000, the whole document.
Database EMBL Accession No. AK026226, XP002197581, Sep. 29, 2000, “Homo sapienscDNA: FLJ22573 fis, clone HSI02387,” the whole document.
Database EMBL Accession No. AAK89843, XP002197582, Aug. 2, 2001, SEQ ID No. 3419 and the whole document.
Database EMBL Accession No. AAK89845, XP002197583, Aug. 2, 2001, SEQ ID No. 3421 and the whole document.
Database EMBL Accession No. ABA07211, XP002197584, Jan. 14, 2002, SEQ ID No. 530 and the whole document.
Database EMBL Accession No. ABA07213, XP002197585, Jan. 14, 2002, SEQ ID No. 532 and the whole document.
Database EMBL Accession No. NP—078936.1, hypothetical protein FLJ22573 [Homo sapiens], Apr. 24, 2003.
Database EMBL Accession No. VT-1097106,Homo sapiens, Nov. 16, 2001.
“Novel TNF Receptor-like molecules and their bioloical uses,” Expert Opin. Ther. Patents 12:1737-1739, 2002; from PCT Application No. WO 02/20762, Amgen, Inc.
Senaldi Giorgio
Silbiger Scott Michael
Theill Lars Eyde
Yeh Richard
Yu Gang
Amgen Inc.
Kaufman Claire
Mohr Randolph N.
Spector Lorraine
LandOfFree
Antibody to TNF receptor-like molecules does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody to TNF receptor-like molecules, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody to TNF receptor-like molecules will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070182